518 related articles for article (PubMed ID: 31404761)
1. Risk of cancer among Finnish multiple sclerosis patients.
Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
[TBL] [Abstract][Full Text] [Related]
2. Common comorbidities and survival in MS: Risk for stroke, type 1 diabetes and infections.
Murtonen A; Kurki S; Hänninen K; Soilu-Hänninen M; Sumelahti ML
Mult Scler Relat Disord; 2018 Jan; 19():109-114. PubMed ID: 29190573
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
4. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
6. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
[TBL] [Abstract][Full Text] [Related]
7. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
Soini E; Joutseno J; Sumelahti ML
Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
[TBL] [Abstract][Full Text] [Related]
9. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
10. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
11. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
12. Medication adherence/persistence among patients with active multiple sclerosis in Finland.
Lahdenperä S; Soilu-Hänninen M; Kuusisto HM; Atula S; Junnila J; Berglund A
Acta Neurol Scand; 2020 Dec; 142(6):605-612. PubMed ID: 32559310
[TBL] [Abstract][Full Text] [Related]
13. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
14. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis in Finland 2018-Data from the national register.
Laakso SM; Viitala M; Kuusisto H; Sarasoja T; Hartikainen P; Atula S; Tienari PJ; Soilu-Hänninen M
Acta Neurol Scand; 2019 Nov; 140(5):303-311. PubMed ID: 31271648
[TBL] [Abstract][Full Text] [Related]
16. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
Lebrun C; Debouverie M; Vermersch P; Clavelou P; Rumbach L; de Seze J; Wiertlevski S; Defer G; Gout O; Berthier F; Danzon A
Mult Scler; 2008 Apr; 14(3):399-405. PubMed ID: 18420778
[TBL] [Abstract][Full Text] [Related]
17. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.
Confavreux C; Saddier P; Grimaud J; Moreau T; Adeleine P; Aimard G
Neurology; 1996 Jun; 46(6):1607-12. PubMed ID: 8649558
[TBL] [Abstract][Full Text] [Related]
18. Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis.
Dolladille C; Chrétien B; Peyro-Saint-Paul L; Alexandre J; Dejardin O; Fedrizzi S; Defer G
Neurotherapeutics; 2021 Jul; 18(3):1657-1664. PubMed ID: 34231126
[TBL] [Abstract][Full Text] [Related]
19. Risk of osteoporotic fractures in multiple sclerosis patients in southwest Finland.
Åivo J; Kurki S; Sumelahti ML; Hänninen K; Ruutiainen J; Soilu-Hänninen M
Acta Neurol Scand; 2017 May; 135(5):516-521. PubMed ID: 27334254
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]